MicroRNA Expression Patterns Related to Merkel Cell Polyomavirus Infection in Human Merkel Cell Carcinoma

Hong Xie1,2, Linkiat Lee1,2, Stefano Caramuta1,2, Anders Höög1,3, Nanna Browaldh4, Viveca Björnhagen5, Catharina Larsson1,2 and Weng-Onn Lui1,2

Merkel cell carcinoma (MCC) is an aggressive and lethal type of neuroendocrine skin cancer. Mutated Merkel cell polyomavirus (MCV) is commonly found in MCC, and leads to upregulation of the survivin oncogene. However, ~20% of MCC tumors do not have detectable MCV, suggesting alternative etiologies for this tumor type. In this study, our aim was to evaluate microRNA (miRNA) expression profiles and their associations with MCV status and clinical outcomes in MCC. We showed that miRNA expression profiles were distinct between MCV-positive (MCV+) and MCV-negative (MCV−) MCCs and further validated that miR-203, miR-30a-3p, miR-769-5p, miR-34a, miR-30a-5p, and miR-375 were significantly different. We also identified a subset of miRNAs associated with tumor metastasis and MCC-specific survival. Functionally, overexpression of miR-203 was found to inhibit cell growth, induce cell cycle arrest, and regulate survivin expression in MCV− MCC cells, but not in MCV+ MCC cells. Our findings reveal a mechanism of survivin expression regulation in MCC cells, and provide insights into the role of miRNAs in MCC tumorigenesis.

Journal of Investigative Dermatology (2014) 134, 507–517; doi:10.1038/jid.2013.355; published online 19 September 2013

INTRODUCTION

Merkel cell carcinoma (MCC) is an aggressive type of neuroendocrine skin cancer that affects elderly and immunosuppressed patients. MCC is rare, but its incidence has increased from 0.15 to 0.6 per 100,000 people during 1986 to 2006, and ~1,500 new cases of MCC diagnosed each year in the United States (Bichakjian et al., 2007; Schrama et al., 2012). Although MCC is less common than malignant melanoma, its associated mortality (33%) is approximately double that of melanoma (15%), and ~50% of patients with advanced disease can only survive for 9 months or less (Tai, 2008).

The molecular events involved in MCC development have been partly elucidated. Recently, a new human polyomavirus called Merkel cell polyomavirus (MCV) was identified in MCC tumors (Feng et al., 2008). This virus was detected in ~80% of MCC tumors, where it is clonally integrated into the tumor DNA with tumor-specific T-antigen mutations (Feng et al., 2008; Shuda et al., 2008). The viral T-antigens are also consistently detected in MCC tumors, and they are required for the maintenance of MCV-positive (MCV+) MCC cell growth (Shuda et al., 2008, 2009; Houben et al., 2010). All these features support the important role of MCV in MCC development. However, ~20% of MCC tumors do not have detectable MCV (Feng et al., 2008; Sihoto et al., 2009), suggesting alternative unknown etiologies that could in turn be related to the clinical presentation and natural course of this tumor type.

To date, possible differences between MCV+ and MCV− MCCs are not well established. Several studies reported an association between MCV status and survival (Sihoto et al., 2009; Bhatia et al., 2010; Laude et al., 2010); however, no such association could be confirmed in other studies (Handschen et al., 2010; Schrama et al., 2011). Recently, Arora et al. (2012) demonstrated that MCV upregulates survivin in MCCs and this oncogene is a therapeutic target for MCC (Arora et al., 2012). Further investigations are still needed to elucidate the molecular mechanisms of MCC biology for a complete understanding of these tumors and to improve clinical management of this disease.

Here, we investigated the role of microRNAs (miRNAs) in MCC. These small RNAs function by guiding sequence-specific gene silencing, and have been shown to have important regulatory roles in many biological processes (Visone and Croce, 2009). miRNAs are deregulated in many cancer types and specific miRNAs are known to have important roles in
Furthermore, miRNAs have been shown to have diagnostic and prognostic values in many cancer types (Calin et al., 2005; Yanaihara et al., 2006; Caramuta et al., 2010). However, the role of miRNAs in MCC has yet to be investigated.

In this study, we characterized the miRNA expression profiles in human MCCs and associated their expressions with MCV status and clinical outcome of the patients. In addition, we determined functional consequences of miR-203 over-expression in MCC cells.

Table 1. Characterization of MCV status in MCC tumors using multiple approaches

| Sample no. | PCR² | Immunohistochemistry³ | MCV status⁴ |
|------------|------|-----------------------|-------------|
| MCCT_1a    | −    | −                     | NA          |
| MCCT_1b    | −    | −                     | NA          |
| MCCT_2a    | −    | −                     | NA          |
| MCCT_2b    | −    | −                     | NA          |
| MCCT_3a    | +    | +                     | ND          |
| MCCT_3b    | +    | +                     | ND          |
| MCCT_4a    | +    | −                     | LT3, PS1    |
| MCCT_4b    | +    | −                     | LT3, PS1    |
| MCCT_5a    | +    | +                     | ND          |
| MCCT_5b    | +    | −                     | LT3, PS1    |
| MCCT_6a    | +    | +                     | ND          |
| MCCT_6b    | +    | −                     | LT3a, PS1   |
| MCCT_7a    | +    | +                     | ND          |
| MCCT_7b    | +    | −                     | LT3, PS1    |
| MCCT_8     | +    | +                     | ND          |
| MCCT_9     | +    | +                     | ND          |
| MCCT_10    | +    | −                     | LT3a, PS1   |
| MCCT_11    | +    | −                     | LT3, PS1    |
| MCCT_12    | −    | −                     | NA          |
| MCCT_13    | −    | −                     | NA          |
| MCCT_14    | +    | −                     | LT3a        |
| MCCT_15    | +    | −                     | LT3a, LT3   |
| MCCT_16    | −    | −                     | NA          |
| MCCT_17    | −    | −                     | NA          |
| MCCT_18    | −    | −                     | LT3a, PS1   |
| MCCT_19    | +    | −                     | LT3a, PS1   |
| MCCT_20    | +    | −                     | LT3a, PS1   |
| MCCT_21    | −    | −                     | NA          |
| MCCT_22    | +    | −                     | LT3a, PS1   |
| MCCT_23    | −    | −                     | NA          |
| MCCT_24    | −    | −                     | NA          |
| MCCT_25    | +    | −                     | LT3, PS1    |
| MCCT_26    | −    | −                     | NA          |

Abbreviations: LT-Ag, large T-antigen; MCV, Merkel cell polyomavirus; NA, not available; ND, not determined; Neg, negative; Pos, positive; −, absent; +, present.

¹a and b refer to primary and recurrent tumors, respectively, of the same patient.
²PCR primers are available in Supplementary Table S1 online.
³Detection of MCV LT-Ag expression was performed using CM2B4 (sc-136172; Santa Cruz Biotechnology) and Ab3 (Rodig et al., 2012) antibodies. The staining intensity was scored based on the nuclear immunoreactivity.
⁴MCV positivity was assessed by PCR amplification of the viral genomic DNA with or without moderate to strong expression of LT-Ag using Ab3 antibody.
⁵Moderate staining in perinuclear areas.
RESULTS

Detection of MCV DNA and large T-antigen expression in MCCs

We evaluated MCV status in a series of 33 MCCs using PCR and immunohistochemistry (IHC). For detection of MCV DNA, we amplified viral sequences from tumor DNA using five primer pairs covering different regions of the viral genome (Supplementary Table S1 online). Among the 33 MCCs, we found seven (21.2%) had amplified products for all five primer pairs, 14 (42.4%) showed partial amplifications, and 12 (36.4%) were completely negative for all primer sets (Supplementary Figure S1a online). The PCR products from the cases with partial amplifications were further verified by sequencing (Table 1 and Supplementary Figure S1b online).

For detection of MCV large T-antigen (LT-Ag) expression, we performed IHC using commercially available CM2B4 antibody and the newly raised Ab3 antibody (Rodig et al., 2012). For CM2B4 antibody, 12 of the 33 samples were
stained positive in the nuclei of tumor cells; three of which also showed cytoplasmic staining. For Ab3 antibody, the overall staining intensity was higher than the CM2B4 antibody and that stained positively in 28 samples (9 strong, 10 moderate, and 9 weak) and the remaining five samples were negative (Table 1 and Supplementary Figure S2 online).

Four MCCs without MCV LT-Ag immunoreactivity (using both antibodies) were also negative for all amplifications of viral DNA. Eight samples, which were negative for PCR detection of MCV DNA, showed weak immunoreactivity in the nucleus of cancer cells for Ab3 and negative for CM2B4. Tumors classified as MCV+ exhibited positive amplification

**Figure 2. Functional consequences of miR-203 overexpression in Merkel cell carcinoma (MCC) cells.** (a) Cell viability was assessed at different time points in MCC cell lines transfected with miR-203 mimic or negative control using WST-1 assay. (b) Trypan blue dye exclusion assay was evaluated at 48 hours after transfection. (c) Cell apoptosis was evaluated by caspase-3 colorimetric assay. (d) Cell cycle was determined by propidium iodide staining using flow cytometry analysis at 48 hours after transfection. The left panel shows representative histograms of cell cycle analysis from a single experiment, and the right panel shows the cell cycle distributions from three independent experiments. Data represent mean ± SD from at least three independent experiments. P-values were calculated using paired Student’s t-test. *P<0.05, **P<0.01, ***P<0.001, NS = not significant.
of the viral genomic DNA and were with or without moderate to strong expression of MCV LT-Ag using Ab3 antibody. Tumors classified as MCV− revealed no PCR amplification of viral DNA and showed weak or no detectable levels of viral LT-Ag using the Ab3 antibody.

Distinct miRNA expression pattern between MCCs with and without MCV
We asked whether miRNA expression patterns were distinct between MCV+ and MCV− MCCs. We first screened global miRNA profiles in 6 MCV+ and 10 MCV− tumors using a microarray approach. After data normalization and filtering, we performed unsupervised clustering of the 244-filtered miRNAs using Spearman rank correlation and complete linkage. The analysis revealed three distinct clusters (Figure 1a), suggesting distinct biological and/or clinical entities of this tumor type. Interestingly, five of the six MCV+ MCCs were grouped together (cluster 2), whereas the remaining MCV+ tumor was found in cluster 3.

We then applied significance analysis of microarray (SAM) to identify the most significant differentially expressed miRNAs between MCV+ and MCV− MCCs. The analysis identified 36 overexpressed and 20 underexpressed miRNAs in MCV+ tumors (false discovery rate, <30%; Supplementary Table S2 online). On the basis of this classifier, we performed clustering analysis of the same cohort, which resulted in similar but clearer separation between MCV+ and MCV− tumors (Figure 1b). Notably, three out of four matched pairs of MCCs with both primary and recurrent tumors were grouped together, indicating similar miRNA expression profiles between the primary and recurrent tumors.

To validate the microarray results, we evaluated the expression levels of eight miRNAs in an extended series of 32 MCCs (12 MCV− and 20 MCV+) by quantitative realtime reverse-transcription–PCR (qRT–PCR). These miRNAs were selected because of their highest SAM scores and/or their involvement in other tumor types. In concordance with the microarray data, we validated significant overexpression of miR-30a-3p, miR-30a-5p, miR-375, miR-34a, and miR-769-5p and underexpression of miR-203 in MCV+ compared with MCV− samples. However, miR-146a and miR-21 were not significantly differentially expressed between MCCs with and without MCV by qRT-PCR (Supplementary Figure S3 online).

miRNAs associated with tumor metastasis and disease-specific survival in MCC
To identify the most significant miRNAs associated with tumor metastasis, we compared miRNA profiles, based on the microarray data, between the primary tumors (n=9) and metastases (n=5) using SAM analysis. We found only overexpressed miRNAs in MCC metastases with false discovery rate <30%. Ninety-two miRNAs were overexpressed in metastases compared with primary tumors (Supplementary Table S3 online). Notably, four miRNAs (miR-150, miR-630, miR-483-5p, and miR-142-3p) had the highest score with a false discovery rate =0. These miRNAs, together with miR-146a (strongly associated with tumor metastasis in other cancer types; Bhaumik et al., 2008; Hurst et al., 2009; Kogo et al., 2011; Hou et al., 2012), were selected for further validation in 17 primary MCCs and nine metastases by qRT-PCR. The results validated overexpression of miR-150 in the metastases compared with the primary tumors (P=0.043; Supplementary Figure S4 online). The other four miRNAs also showed relatively higher expression levels in the metastases compared with the primary tumors; however, the differences were not statistically significant (Supplementary Figure S4 online).

To identify prognostic miRNAs associated with disease-specific survival, we applied SAM survival analysis on the microarray cohort (n=12), which resulted in 26 overexpressed and 118 underexpressed miRNAs most correlated with shorter disease-specific survival in MCC (false discovery rate <12%; Supplementary Table S4 online).

Functional consequences of miR-203 overexpression in MCC cells
Given that miR-203 has an important role in multiple tumor types (Bo et al., 2011; Li et al., 2011; Noguchi et al., 2012; Jin et al., 2013) and its expression was significantly lower in MCV+ than MCV− MCC tumors, we asked whether miR-203 has a role in MCC. We ectopically expressed miR-203 using a miRNA mimic in MCC cell lines and investigated its effect on cell growth, cell cycle, and apoptosis. Using WST-1 and trypan blue exclusion assays, we observed that the cell growth was significantly decreased in the miR-203 mimics-treated cells compared with its negative control for all three MCV− MCC cell lines (Figure 2a and b). However, we did not observe any significant effect on cell apoptosis upon overexpression of miR-203, as evaluated by caspase-3 activity (Figure 2c). We next sought to determine whether miR-203 regulates cell cycle progression in MCC cells. Indeed, we found that all three MCV− MCC cells transfected with miR-203 mimic had significantly higher fraction of cells in the G1 phase, whereas the cells in the G2 phase were significantly lower than negative control (Figure 2d). Interestingly, overexpression of miR-203 in MCV− WaGa cells had no significant effect on cell proliferation or cell cycle progression (Supplementary Figure S5 online).

miR-203 suppresses survivin expression only in MCV− MCC cells
miR-203 was recently shown to target survivin (also known as BIRC5) in prostate (Saini et al., 2011b), laryngeal (Bian et al., 2012), and hepatocellular (Wei et al., 2013) cancer cells. Interestingly, survivin expression was recently found higher in MCV+ compared with MCV− MCCs (Arora et al., 2012). This prompted us to investigate whether miR-203 also regulates survivin expression in MCCs. We overexpressed miR-203 in MCC cell lines and assessed its effect on survivin expression at mRNA and protein levels, as determined by qRT-PCR and western blot analysis, respectively. We found that survivin expression was significantly decreased at mRNA and protein levels upon overexpression of miR-203 in MCV− MCC cells, but not in MCV+ MCC cells (Figure 3a).

MCV T-antigens regulate survivin expression in MCV+ but not in MCV− MCC cells
MCV LT-Ag has been shown to regulate survivin expression in MCV+ MCC cells (Arora et al., 2012). Given that we
observed differences in miR-203-mediated survivin expression regulation in MCV+ and MCV− MCC cells, we asked whether MCV LT-Ag also differentially regulates survivin expression between MCC cells with and without the viral factor. We silenced MCV T-Ags using short hairpin RNA (shRNA) constructs targeting the common T-Ag exon 1 sequence in MCV+ WaGa cells and overexpressed wild-type (LT206) or truncated (LT339) MCV LT-Ag in MCV− MCC14/2 cells, and assessed their effects on survivin expressions at both mRNA and protein levels. As shown in Figure 3b, survivin expression was significantly decreased upon silencing of MCV T-Ags. However, we did not observe any significant increase of survivin expression in MCV− MCC14/2 cells expressing either wild-type or truncated MCV LT-Ag (Figure 3c). The results are reproducible in two other MCV− MCC cell lines (MCC13 and MCC26) (data not shown).

**DISCUSSION**

In this study, we used a genomic approach to characterize miRNA expression profiles of human MCCs. Our results reveal a set of miRNAs associated with MCV status, tumor metastasis, and disease-specific survival in MCC patients.

**miRNA expressions in MCC tumors with and without MCV**

We show that MCV+ and MCV− tumors are distinct based on miRNA expression profiles. The finding is consistent with the recent study showing distinct mRNA expression profiles...
between MCCs with and without MCV (Harms et al., 2013). Our clustering analysis grouped the MCC tumors into three distinct subgroups, suggesting biological or clinical heterogeneity of this tumor type. Notably, we found that the MCC—tumors were grouped into two separate clusters, whereas majority of the MCC+ tumors were grouped together, suggesting distinct molecular mechanisms underlying the pathogenesis of MCC—MCCs. Concordantly, Harms et al. (2013) also showed that MCC—MCCs are more heterogeneous than MCC+ tumors based on mRNA expression profiling (Harms et al., 2013).

miR-203 functions as a tumor suppressor in MCC cells
Using SAM analysis, we found a subset of differentially expressed miRNAs between MCC+ and MCC—MCCs. Among them, miR-203 was found significantly lower in MCC+ tumors, which was further validated in a larger cohort of MCCs by qRT-PCR. miR-203 is commonly downregulated in human cancers (Chiang et al., 2011; Saini et al., 2011b; Boll et al., 2013; Jin et al., 2013); however, its increased expression has also been observed in breast cancer (Ru et al., 2011), pancreatic cancer (Ikenaga et al., 2010), and ovarian cancer (Iorio et al., 2007). Functionally, miR-203 has been shown to suppress targets involved in oncogenic processes and pathways in different cancer types (Bo et al., 2011; Li et al., 2011; Saini et al., 2011a; Boll et al., 2013). In this study, we also demonstrate that miR-203 overexpression inhibits cell growth and induces cell cycle arrest in MCC—MCC cells, suggesting its tumor suppression function in non-viral-associated MCC.

Survivin is one of the direct targets of miR-203 in several cancer types (Bian et al., 2012; Jin et al., 2013; Wei et al., 2013). We speculated that survivin may also be regulated by miR-203 in MCC, because of its higher expression level in MCC+ than MCC—MCCs and its inverse expression association with miR-203. In line with our speculation, we demonstrate that miR-203 regulates survivin expression only in MCC—MCC cells. However, in MCC+ MCC cells, survivin expression is regulated by MCV LT-Ag oncoprotein. Recently, YM155, a survivin inhibitor, has been shown to inhibit both MCC+ and MCC—MCC cell growth in vitro (Arora et al., 2012). Taken together, we propose that survivin is commonly deregulated in MCCs, and it is regulated by MCV LT-Ag in MCC+ MCCs or miR-203 in MCC—MCCs.

miRNAs associated with tumor metastasis
We identify a subset of miRNAs associated with tumor metastasis in MCC. Among the miRNAs associated with tumor metastasis, increased expression of miR-150 in MCC metastases is validated by qRT-PCR. This miRNA is highly expressed in hematopoietic cells, and has important roles in hematopoeisis and immune response (Xiao et al., 2007; Zhou et al., 2007; Bezman et al., 2011; Zheng et al., 2012). We noted that seven of the nine tumor metastases included for qRT-PCR analysis are lymph node metastases from MCC primary tumors. The observed higher expression of miR-150 in the MCC metastases is plausibly due to the high percentage of lymphocytes present in the lymph nodes. Further investigations are warranted to evaluate whether miR-150 expression is differentially expressed between the lymph node and organ metastases, as well as its functional role in MCC cells.

Among the survival-associated miRNAs, several of them have been associated with tumor progression and survival in other cancer types. For examples, higher expression of miR-93 has been associated with poor survival in serous ovarian cancer (Nam et al., 2008), and lower expression of miR-146a is associated with poor prognosis in gastric cancer (Kogo et al., 2011) and natural killer/T cell lymphoma (Paik et al., 2011). miR-146a is known to function as a tumor suppressor in myeloid malignancies (Zhao et al., 2011) and a modulator of the T lymphocyte-mediated immune response (Huffaker et al., 2012). Given that high numbers of intratumoral T lymphocytes in MCC tumors are associated with favorable survival (Iyer et al., 2011; Paulson et al., 2011; Sihto et al., 2012), it is tempting to speculate that miR-146a modulates the immune response of the T cells specific for MCV LT-Ag in MCC. Further validation of these prognostic miRNAs in a larger cohort of MCC patients remains to be determined.

Prevalence of MCV infection in MCC tumors
In consistence with previous studies (Feng et al., 2008; Becker et al., 2009; Sastre-Garau et al., 2009; Sihto et al., 2009; Arora et al., 2012; Harms et al., 2013), we found the majority of MCC tumors to be MCV+. However, a subset of MCC tumors were MCV−, which is not in agreement with the recent findings by Rodig et al. (2012), who detected MCV LT-Ag expression in almost all MCC tumors using the Ab3 mAb. We used the same antibody concentration (0.6 μg ml−1) and scoring criteria for evaluating MCV LT-Ag expression in our cohort. However, partly different interpretations of MCV positivity based on Ab3 immunoreactivity were applied. In the study of Rodig et al. (2012), weak immunoreactivity (scored as 1+) of Ab3 was interpreted as MCV+. In our study, we could not detect MCV viral genome in those cases with weak immunoreactivity (1+), and therefore scored these cases as MCV−. In Rodig’s study, all cases with weak immunoreactivity had very low MCV copy number (<1 copy per cell) that is similar to those cases with lack of immunoreactivity for Ab3, raising a question for the inclusion of 1+ signal as MCV+. Furthermore, previous studies have consistently reported a subset of MCC tumors are MCV− using different approaches (Feng et al., 2008; Becker et al., 2009; Sastre-Garau et al., 2009; Sihto et al., 2009; Arora et al., 2012; Harms et al., 2013). Taken together, we find that the presently available data suggest that a subset of MCCs is MCV−.

In summary, we report miRNA signatures related to MCV infection and clinical outcomes in human MCC. Our findings support that MCV+ and MCV− tumors involved in different genetic pathways, and suggest that MCV− tumors are more heterogeneous than the MCV+ tumors. In addition, we demonstrate the functional role of miR-203 in MCV− MCC cells, suggesting its role in the pathogenesis of non-viral-associated MCC.
miRNA Expression Profiling in Merkel Cell Carcinoma

Table 2. Summary of the clinical features of 26 MCC patients in this study

| Characteristic (no. of informative) | No. of cases |
|-------------------------------------|-------------|
| No. of tumors                        | 33          |
| Gender (n = 26)                      |             |
| Male                                | 11          |
| Female                              | 15          |
| Age at diagnosis (n = 26) (years)   |             |
| Median = 77 (range 20–91)           | 14          |
| ≤77                                 | 14          |
| >77                                 | 12          |
| Lesion type (n = 33)                 |             |
| Primary                             | 18          |
| Local recurrence                    | 6           |
| Metastasis                          | 9           |
| Primary tumor size (n = 24) (cm)    |             |
| Median = 2.4 (range 0.7–15)         | 12          |
| ≤2.4                                | 12          |
| >2.4                                | 12          |
| Primary tumor location (n = 26)     |             |
| Head and neck                       | 15          |
| Arm                                 | 5           |
| Other (thigh, gluteal region, groin)| 6           |
| Survival (n = 25) (months)          |             |
| <12                                 | 8           |
| 12–60                               | 9           |
| >60                                 | 8           |
| Outcome (n = 25)                    |             |
| Alive                               | 3           |
| Died of other causes                | 8           |
| DOD                                 | 14          |
| MCV status (n = 33)                 |             |
| Positive                            | 21          |
| Negative                            | 12          |

Abbreviations: DOD, died of disease; LT-Ag, large T-antigen; MCV, Merkel cell polyomavirus.

Detection of MCV genomic DNA combined with LT-Ag immunoreactivity.

DNA and total RNA extraction

For clinical samples, a 10-µm FFPE section from each specimen was subjected to genomic DNA extraction using QiAamp DNA FFPE Tissue kit (Qiagen, Hilden, Germany). Another 10-µm FFPE section was subjected to total RNA extraction using TRIzol reagent (Invitrogen, Carlsbad, CA) following a previously described method (Ma et al., 2009). For MCC cell lines, genomic DNA was extracted using Qiagen DNAeasy Blood and Tissue kit, and total RNA was extracted using mirVana miRNA isolation kit (Applied Biosystems/Ambion, Austin, TX). Plasmid was purified using Qiagen Plasmid Mini Kit. The concentrations of DNA and RNA were measured with a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE).

MCV DNA detection by PCR and sequencing

The presence of MCV DNA in tumor samples was detected by PCR using previously published primer sets (Feng et al., 2008; Duncavage et al., 2009; Jung et al., 2011) (Supplementary Table S1 online). PCR was performed using 100 ng genomic DNA from tumor samples and cell lines, or 10 ng plasmid DNA. The MKL-1 cell line (Shuda et al., 2008) and the pMCV-R17a (Addgene, Cambridge, MA) plasmid DNA were used as positive controls. The MCC13 cell line (Shuda et al., 2008) and no DNA template were used as negative controls. All PCR amplifications were repeated two times at different time using different DNA preparations. The PCR products from the tumor samples that did not have amplicons for all five primer sets were purified by QiAquick Gel Extraction kit (Qiagen) or ExoSAP-IT (USB Corporation/Affymetrix, Cleveland, OH), and sequenced at the KIGene core facility.

miRNA microarray experimentation and analyses

miRNA expression profiling was performed using Agilent’s human miRNA microarray (miRBase release 10.1; Agilent, Santa Clara, CA), as described previously (Caramuta et al., 2010). In brief, 200 ng of total RNA was labeled with Cy3 and then hybridized onto the arrays for 20 hours at 55 °C. Slides were scanned using Agilent microarray scanner (Agilent, Santa Clara, CA). The images were processed with Feature Extraction Software 10.7.3.1 (Agilent). Intensity values were normalized and median centered using Cluster 3.0. Only normalized miRNAs with <20% missing values across the samples were used for clustering and statistical analyses. Hierarchical clustering was performed based on complete linkage with the Spearman rank correlation coefficient in Cluster 3.0. Feature selection was performed using a fivefold cross-validation, and the miRNAs with the highest difference in expression between the primary and recurrent tumors were used for further analyses. The miRNA expression dataset was visualized using the maANOVA R package (Smyth et al., 2005). The miRNAs that were significantly different in expression in the primary and recurrent tumors were subjected to functional enrichment analysis using the DAVID bioinformatic database (Huang et al., 2009). The miRNAs that were significantly different in expression in the primary and recurrent tumors were subjected to functional enrichment analysis using the DAVID bioinformatic database (Huang et al., 2009).
correlation using Cluster 3.0 and visualized with Treeview version 1.60 (de Hoon et al., 2004). SAM (http://www-stat.stanford.edu/~tibs/SAM/) was used to determine the association of miRNAs with MCV status, tumor metastasis, and disease-specific survival. Microarray data are available at NCBI Gene Expression Omnibus (GEO accession number GSE43699).

qRT-PCR
Expression of mature miRNAs and mRNA was quantified by qRT-PCR using the Applied Biosystems 7900HT or StepOne Plus Real-time PCR systems. For mature miRNAs, cDNA was synthesized from 50 ng (for FFPE samples) or 100 ng (for cell lines) total RNAs using TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems). Pre-designed TaqMan MicroRNA Assays for mir-30a-3p (ID 000416), mir-30a-5p (ID000417), miR-34a (ID000426), miR-148a (ID000470), miR-769-5p (ID001998), miR-21 (ID00397), miR-375 (ID000564), miR-203 (ID00507), miR-483-5p (ID002338), miR-750 (ID000473), miR-142-3p (ID00464), miR-146a (ID00468), and miR-630 (ID001563) were purchased from Applied Biosystems. RNU6B (ID001093) was used for normalization of miRNA expression. For mRNA quantification, cDNA was synthesized from 100 ng total RNAs using High Capacity cDNA Reverse Transcription kit (Applied Biosystems). qRT-PCR was performed for BIRC5 (Hs04194329_s1; Applied Biosystems) and normalized against 18S ribosomal RNA (Hs9999990_1_s1; Applied Biosystems). All reactions were performed in triplicate and relative expression levels were reported as $2^{-\Delta\Delta C_T}$.

Construction of expression and shRNA vectors
Wild-type (LT206, plasmid 28190) and truncated (LT339, plasmid 28193) MCC LT-Ag expression vectors (Shuda et al., 2008) were purchased from Addgene. As a negative control, we used an empty vector, which was constructed by deleting the insert from the LT339 plasmid by digestion with XbaI and NheI (New England Biolabs, Ipswich, MA).

We cloned three shRNA vectors targeting the common exon 1 of MCC T-antigens between BglII and KpnI sites of plasmid pCDNA3-U6M2 (Taft et al., 2011). The targeting sequences of the shRNAs are described in Supplementary Figure S6 online. All constructs were confirmed by sequencing at KIGene core facility.

Transfection
For small RNA transfection, MCC13, MCC14/2, and MCC26 cells were transfected with 10 nM of mir-203 mimic (Applied Biosystem) or miRNA mimic Negative Control no. 1 (Applied Biosystem) using Lipofectamine RNAiMAX Reagent (Invitrogen) following the reverse transfection method as described in the manufacturer's protocol. WaGa cells were transfected with 10 pmol per 1 x 10^6 cells of mir-203 mimic or negative control using Lipofectamine RNAiMAX Reagent (Invitrogen). MKL-1 cells were transfected with 20 pmol per 1 x 10^6 cells of miR-203 mimic or negative control by Nucleofector Kit V (Amaxa/Lonza, Basel, Switzerland) using program A-24. For MCC LT-Ag expression vector transfection, MCC14/2 cells were transfected with LT206, LT339, or empty vector (2 μg per well in a 6-well plate) using Lipofectamine 2000 Reagent (Invitrogen). For shRNA vector transfection, 2 μg shRNA vector (pcDNA3-U6M2, shTA1, shTA2, and shTA3) were transfected into 1 x 10^6 WaGa cells by Nucleofector Kit V and program D-24.

Western blot analysis
At 48 or 72 hours after transfection, cells were collected and lysed for immunoblot analysis as described previously (Xie et al., 2012). Survivin antibody (1:1,000; no. 2808; Cell Signaling Technology, Danvers, MA) was used to determine survivin expression, CM2B4 (1:200, sc-136172; Santa Cruz Biotechnology, Santa Cruz, CA) was used to determine MCC LT-Ag expression, glyceraldehyde-3-phosphate dehydrogenase (1:10,000, sc-47724; Santa Cruz Biotechnology) or β-tubulin (1:1,000; no. 2128; Cell Signaling Technology) was used for normalization. Signals were detected by LAS-1000 Image Analyzer (Fujifilm, Tokyo, Japan), and protein expressions were quantified using Image Gauge version 4.0 (Fujifilm).

Immunohistochemistry
CM2B4 and Ab3 (kindly provided by Dr James A. DeCaprio, DanaFarber Cancer Institute, Boston, MA) antibodies were used for IHC to determine MCV LT-Ag expression in clinical samples. Four-μm tissue sections were deparaffinized, rehydrated, and blocked for endogenous peroxidase with 3% hydrogen peroxide. Antigen retrieval was performed at ~99°C in citrate buffer (pH 6.0) for CM2B4 or Tris-EDTA buffer (pH 9.0; for Ab3). The antibodies (CM2B4, 1:100; Ab3, 0.6 μg ml^-1) were diluted with Dako REAL antibody diluent (Dako Denmark A/S, Glostrup, Denmark), applied on the tissues, and incubated overnight at 4°C. Anti-mouse/rabbit horseradish peroxidase–conjugated antibody was applied on tissues for 40 minutes at room temperature before developing with Dako REAL EnVision Detection System (Dako), and counterstained with Mayer’s hematoxylin. The immunoreactivity was examined under a light microscope, and scored based on nuclear immunoreactivity by a pathologist (A Höög).

Cell growth analysis
For WST-1 assay, 8.0 x 10^3 cells per well (MCC13 and MCC14/2), 4.0 x 10^3 cells per well (MCC26), or 4.0 x 10^4 cells per well (WaGa) in 100 μl culture medium were seeded into 96-well plate. At different time points (0, 24, 48, 72, or 96 hours after transfection), 10 μl of WST-1 reagent was added and incubated for 3 hours at 37°C. Absorbance was determined at 450 nm (measurement) and 650 nm (reference) using a VERSamax microplate reader (Molecular Devices, Sunnyvale, CA). Each experimental group consisted of eight replicates for each time point. All experiments were performed at least three times independently. Cell growth rate was evaluated by subtracting the background absorbance individually and normalized to 0-hour time point.

For trypan blue exclusion assays, cells were collected at 48 or 72 hours after transfection, stained with 0.4% trypan blue stain (Invitrogen), and analyzed using a TC10 automated cell counter (Bio-Rad, Hercules, CA). The total live cells in miR-203 mimic–transfected cells were normalized to the miRNA mimic–negative control.

Cell apoptosis assay
Apoptosis assay was performed using caspase-3 colorimetric assay kit (BioVision, Mountain View, CA), as described previously (Xie et al., 2012). In brief, 5 x 10^5 cells were transfected and harvested after 48 hours of transfection, and lysed in 50 μl of chilled cell lysis buffer for 10 minutes. A total of 50 μl of protein lystate (4 mg ml^-1) was mixed with 50 μl of 2 x Reaction Buffer and 5 μl of 4 μM caspase-3 substrate, and incubated for 2 hours at 37°C. Detection of the caspase-3
miRNA Expression Profiling in Merkel Cell Carcinoma

H Xie et al.

miRNA Expression Profiling in Merkel Cell Carcinoma

cleavage products was measured at 405 nm using a VERSAmax microplate reader (Molecular Devices). Relative caspase-3 activity was determined by the absorbance values of the samples compared with the respective negative controls. All experiments were replicated three times independently.

Cell cycle analysis

At 48 or 72 hours after transfection, 1 × 10⁶ cells were washed with phosphate-buffered saline and fixed in cold 50% ethanol for 1 hour. After washing with phosphate-buffered saline and treating with RNase A (0.2 mg ml⁻¹) for 1 hour at 37°C, the cells were stained with propidium iodide (0.04 mg ml⁻¹). Cell cycle analysis was performed using flow cytometry (Cytomics FC 500; Beckman Coulter, Brea, CA) and FlowJo software version 7.6.2 (Tree Star, Ashland, OR). All experiments were performed independently in triplicate.

Statistical analyses

Statistica 7.0 (StatSoft, Tulsa, OK) or Microsoft Office Excel 2007 was used for statistical calculations, unless otherwise stated. The comparison between miRNA expressions in different groups was conducted using unpaired Student’s t-test. Paired Student’s t-test was performed to analyze transfection experiments. Patients who are alive or died of MCC-unrelated reasons were considered as censored. All the analyses were two-tailed and P-values < 0.05 were regarded as significant.

CONFLICT OF INTEREST

The authors state no conflict of interest.

ACKNOWLEDGMENTS

This work was supported by the Swedish Research Council (523-2009-3517; 521-2010-3518), the Åke Olsson’s Foundation for Haematological Research, and the Swedish Cancer Foundation, the Axel and Signe Lagerman’s Donation Foundation, Karolinska Institutet, and Stockholm County Council. HX is a recipient of the Karolinska Institutet PhD support program. We thank Susanne Agartz, Lisa Viberg, and Lisa Ånfalk from Biobank of Karolinska University Hospital for all clinical samples, Dr Nancy L Krett (Northwestern University) for providing Mink-1 cell line, Dr Jürgen C Becker (Medical University of Graz) for providing WiGa cell line, Dr James A DeCaprio (Dana-Farber Cancer Institute) for providing AB3 antibody, Dr Yu Ming (Karolinska Institute) for providing glyceraldehyde-3-phosphate dehydrogenase primers, Prof Johansson (Karolinska Institute) for the plasmid pCDNA3-U6M2, and Zhangsen Huang (Karolinska Institutet) for providing MKL-1 cell line, Dr Ju¨rgen C Becker (Medical University of Graz) for all clinical samples, Dr Nancy L Krett (Northwestern University) for providing glyceraldehyde-3-phosphate dehydrogenase primers, Per Johansson (Karolinska Institutet) for technical support of flow cytometry. We also thank the staff at the KIGene core facility for sequencing service, and all members of Medical Genetics research group for helpful discussions and suggestions.

SUPPLEMENTARY MATERIAL

Supplementary material is linked to the online version of the paper at http://www.nature.com/jid

REFERENCES

Arora R, Shuda M, Guastafierro A et al. (2012) Survivin is a therapeutic target in Merkel cell carcinoma. Sci Transl Med 4:133–56
Becker JC, Houben R, Ugurel S et al. (2009) MC polyomavirus is frequently present in Merkel cell carcinoma of European patients. J Invest Dermatol 129:248–50
Bezeman NA, Chakraborty T, Bender T et al. (2011) miR-150 regulates the development of NK and iNKT cells. J Exp Med 208:2717–31
Bhatia K, Goedert JJ, Modali R et al. (2010) Merkel cell carcinoma subgroups by Merkel cell polyomavirus DNA relative abundance and oncogene expression. Int J Cancer 126:2240–6
Bhakumik D, Scott GK, Schokpur S et al. (2008) Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene 27:5643–7
Bian K, Fan J, Zhang X et al. (2012) MicroRNA-203 leads to G1 phase cell cycle arrest in laryngeal carcinoma cells by directly targeting survivin. FEBS Lett 586:804–9
Bichakjian CK, Lowe L, Lao CD et al. (2007) Merkel cell carcinoma: critical review with guidelines for multidisciplinary management. Cancer 110:1–12
Bo J, Yang G, Hua K et al. (2011) microRNA-203 suppresses bladder cancer development by repressing bcl-w expression. FEBS J 278:786–92
Boll K, Reiche K, Kasack K et al. (2013) MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Oncogene 32:277–85
Calin GA, Ferracin M, Cimmino A et al. (2005) A microRNA signature associated with progression and progression in chronic lymphocytic leukemia. N Engl J Med 353:1793–801
Caramuta S, Eghhazi S, Rodolfo M et al. (2010) MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. J Invest Dermatol 130:2062–70
Chiang Y, Song Y, Wang Z et al. (2011) Aberrant expression of miR-203 and its clinical significance in gastric and colorectal cancers. J Gastrointest Surg 15:63–70
de Hoon MJ, Imoto S, Nolan J et al. (2004) Open source clustering software. Bioinformatics 20:1453–4
Duncavage EJ, Zehnbauer BA, Pleifler JD (2009) Prevalence of Merkel cell polyomavirus in Merkel cell carcinoma. Mod Pathol 22:516–21
Feng H, Shuda M, Chang Y et al. (2008) Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 319:1096–100
Handschem J, Muller D, Depprich RA et al. (2010) The new polyomavirus (MCVyV) does not affect the clinical course in MCCs. Int J Oral Maxillofac Surg 39:1086–90
Harms PW, Patel RM, Verhaegen ME et al. (2013) Distinct gene expression profiles of viral- and nonviral-associated Merkel cell carcinoma revealed by transcriptome analysis. J Invest Dermatol 133:936–45
Hou Z, Yin H, Chen C et al. (2012) MicroRNA-146a targets the L1 cell adhesion molecule and suppresses the metastatic potential of gastric cancer. Mol Med Report 6:501–6
Houben R, Shuda M, Weinkam R et al. (2010) Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens. J Virol 84:7064–72
Huffaker TB, Hu R, Rutsch MC et al. (2012) Epistasis between microRNAs 155 and 146a during T cell-mediated antitumor immunity. Cell Rep 2:1697–709
Hurst DR, Edmonds MD, Scott GK et al. (2009) Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res 69:1279–83
Ikenaga N, Ohuchida K, Mizumoto K et al. (2010) MicroRNA-203 expression as a new prognostic marker of pancreatic adenocarcinoma. Ann Surg Oncol 17:3120–8
Iorio MV, Croce CM (2012) MicroRNA involvement in human cancer. Carcinogenesis 33:1126–33
Iorio MV, Visone R, Di Leva G et al. (2007) MicroRNA signatures in human ovarian cancer. Cancer Res 67:6869–707
Iyer JG, Afanasiev OK, McClurkan C et al. (2011) Merkel cell polyomavirus-specific CD8+ and CD4+ T-cell responses identified in Merkel cell carcinomas and blood. Clin Cancer Res 17:6671–80
Jin J, Deng J, Wang F et al. (2013) The expression and function of microRNA-203 in lung cancer. Tumour Biol 34:349–57
Jung HS, Choi YL, Choi JS et al. (2011) Detection of Merkel cell polyomavirus in Merkel cell carcinomas and small cell carcinomas by PCR and immunohistochemistry. Histol Histopathol 26:1231–41
Kogo R, Mimori K, Tanaka F et al. (2011) Merkel cell polyomavirus molecular features in tumour and non tumour specimens from patients with Merkel cell carcinoma. PLoS Pathogen 6:e1001076
Li J, Chen Y, Zhao J et al. (2011) miR-203 reverses chemoresistance in p53-mutated colon cancer cells through downregulation of Akt2 expression. Cancer Lett 304:52–9
Ma Z, Lui WO, Fire A et al. (2009) Profiling and discovery of novel miRNAs from formalin-fixed, paraffin-embedded melanoma and nodal specimens. J Mol Diagn 11:420–9
Nam EJ, Yoon HJ, Kim SW et al. (2008) MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 14:2690–5
Noguchi S, Mori T, Otsuka Y et al. (2012) Anti-oncogenic microRNA-203 induces senescence by targeting E2F3 protein in human melanoma cells. J Biol Chem 287:11769–77
Paik JH, Jang JY, Jeon YK et al. (2009) Merkel cell carcinoma of the skin: pathological and molecular evidence for a causative role of MCV in oncogenesis. J Invest Dermatol 122:4645–53
Shuda M, Feng H, Kwun HJ et al. (2008) T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proc Natl Acad Sci USA 105:16272–7
Sihto H, Bohling T, Kavola H et al. (2012) Tumor infiltrating immune cells and outcome of Merkel cell carcinoma: a population-based study. Clin Cancer Res 18:2872–81
Sihto H, Kukko H, Koljonen V et al. (2009) Clinical factors associated with Merkel cell polyomavirus infection in Merkel cell carcinoma. J Natl Cancer Inst 101:938–45
Taft RJ, Hawkins PG, Mattick JS et al. (2011) The relationship between transcription initiation RNAs and CCCTC-binding factor (CTCF) localization. Epigenet Chromatin 4:13
Tae P (2008) Merkel cell cancer: update on biology and treatment. Curr Opin Oncol 20:196–200
Visone R, Croce CM (2009) MiRNAs and cancer. Am J Pathol 174:1131–8
Wei W, Wanjun L, Hui S et al. (2013) miR-203 inhibits proliferation of HCC cells by targeting survivin. Cell Biochem Funct 31:82–5
Xiao C, Calado DP, Galler G et al. (2007) MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell 131:146–59
Xie H, Zhao Y, Caramuta S et al. (2012) miR-205 expression promotes cell proliferation and migration of human cervical cancer cells. PLoS One 7:e46990
Yanaihara N, Caplen N, Bowman E et al. (2006) Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9:189–98
Zhao JL, Rao DS, Boldin MP et al. (2011) NF-kappaB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies. Proc Natl Acad Sci USA 108:9184–9
Zheng Q, Zhou L, Mi QS (2012) MicroRNA miR-150 is involved in Valpha14 invariant NKT cell development and function. J Immunol 188:2118–26
Zhou B, Wang S, Mayr C et al. (2007) mir-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely. Proc Natl Acad Sci USA 104:7080–5

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/